ANKRD9

Across TCGA pan-cancer cohorts, ANKRD9 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ANKRD9 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher ANKRD9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANKRD9 expression acts as an unfavorable survival marker.

SKCM are the cancer types where ANKRD9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.138	0.873	<.001	36	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

ANKRD9–SKCM (OS)

Open the SKCM breakdown →